<DOC>
	<DOCNO>NCT00862355</DOCNO>
	<brief_summary>Bioequivalence study SPARC147609</brief_summary>
	<brief_title>Bioequivalence Study SPARC147609 Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Subjects meet follow criterion consider enrollment study : Availability subject entire study period willingness adhere protocol requirement . Patients document diagnosis Ovarian Cancer eligible receive dose 50mg/m2 Doxorubicin liposome ( preferably concomitant medication , however , consider necessary , document give ) . Patients least 18years age old . iv . Subjects evidence underlie disease ( except ovarian cancer ) screen medical history whose physical examination perform within 21 day prior commencement study . Patients Performance â‰¤ 2 ECOG performance scale . vi . Subjects whose screen laboratory value within normal limit consider clinical Investigator/CoInvestigator clinical significance . Informed consent form give write form . History presence significant : Allergy Significant history hypersensitivity idiosyncratic reaction Doxorubicin Hydrochloride and/or related compound etc . Cardiovascular , pulmonary , hepatic , renal , gastrointestinal , endocrine , immunologic , dermatologic , musculoskeletal , neurological psychiatric disease . Alcohol dependence , alcohol abuse drug abuse addiction recreational drug within past one year . Clinically significant illness ( except ovarian cancer ) within 4 week start study v. Positive result HIV , HCV , RPR HBsAg . Use enzymemodifying drug ( like Phenytoin , Carbamazepine , Barbiturates , Gresiofulvine etc . ) previous 30 day day 1 study study . Donation 350 mL blood previous 90 day day 1 study . Participation another clinical trial within precede 90 day study start Subjects : Systolic blood pressure le 90 mm Hg 140 mm Hg Diastolic blood pressure le 60 mm Hg 90 mm Hg Pulse rate 60/min . 100/min</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Carcinoma</keyword>
	<keyword>Ovary</keyword>
	<keyword>Carcinoma Ovary</keyword>
</DOC>